CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia ; volume:11 ; number:1 ; day:17 ; month:12 ; year:2019 ; pages:1-9 ; date:12.2019
Alzheimer's research & therapy ; 11, Heft 1 (17.12.2019), 1-9, 12.2019
- Creator
-
Clarke, Mica T. M.
Brinkmalm, Ann
Foiani, Martha S.
Woollacott, Ione O. C.
Heller, Carolin
Heslegrave, Amanda
Keshavan, Ashvini
Fox, Nick C.
Schott, Jonathan M.
Warren, Jason D.
Blennow, Kaj
Zetterberg, Henrik
Rohrer, Jonathan D.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-019-0564-2
- URN
-
urn:nbn:de:101:1-2020040800403889152662
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Clarke, Mica T. M.
- Brinkmalm, Ann
- Foiani, Martha S.
- Woollacott, Ione O. C.
- Heller, Carolin
- Heslegrave, Amanda
- Keshavan, Ashvini
- Fox, Nick C.
- Schott, Jonathan M.
- Warren, Jason D.
- Blennow, Kaj
- Zetterberg, Henrik
- Rohrer, Jonathan D.
- SpringerLink (Online service)
Other Objects (12)
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration
Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration
Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Fluid biomarkers in Alzheimer’s disease – current concepts
Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications
Plasma biomarkers increase diagnostic confidence in patients with Alzheimer’s disease or frontotemporal lobar degeneration
Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimer’s disease
Levels of ADAM10 are reduced in Alzheimer’s disease CSF
A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood
BACE1gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study